[go: up one dir, main page]

PE20120657A1 - Compuesto para el tratamiento de trastornos metabolicos - Google Patents

Compuesto para el tratamiento de trastornos metabolicos

Info

Publication number
PE20120657A1
PE20120657A1 PE2011001632A PE2011001632A PE20120657A1 PE 20120657 A1 PE20120657 A1 PE 20120657A1 PE 2011001632 A PE2011001632 A PE 2011001632A PE 2011001632 A PE2011001632 A PE 2011001632A PE 20120657 A1 PE20120657 A1 PE 20120657A1
Authority
PE
Peru
Prior art keywords
compound
cycloalkyl
alkyl
substituted
treatment
Prior art date
Application number
PE2011001632A
Other languages
English (en)
Inventor
Oscar Barba
Peter Timothy Fry
Matthew Colin Thor Fyfe
William Gattrell
Thomas Martin Krulle
Colin Peter Sambrook-Smith
Karen Lesley Schofield
Donald Smyth
Alan John William Stewart
David French Stonehouse
Simon Andrew Swain
Martin James Procter
Revathy Perpetua Jeevaratnam
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of PE20120657A1 publication Critical patent/PE20120657A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE p ES 1-2; Z ES CHR1, NR2 CUANDO p ES 2 Y, -N-CH2-FENILO SUSTITUIDO O NO CUANDO Z ES 1; R1 ES -N-(CH3)-C(O)-O-ALQUILO C2-C4, -N-(CH3)-C(O)-O-CICLOALQUILO C3-C6 DONDE EL CICLOALQUILO ES SUSTITUIDO O NO POR ALQUILO C1-C4; R2 ES -C(O)-O-ALQUILO C2-C4, -C(O)-O-CICLOALQUILO C3-C6 SUSTITUIDO O NO, ENTRE OTROS; Q ES -O-, -O-CH2, O-CH(CH3)-, -CH2-O, CH(CH3)-O-; X ES FENILO, HETEROARILO DE 5-6 MIEMBROS CON 1 O MAS HETEROATOMOS DE N, O, S; R3 Y R3a SON CADA UNO H, F, Cl, ENTRE OTROS; Y ES UN ENLACE, CH2, CHME-; R4 ES H, O PUEDE FORMAR CON Y (CUANDO Y ES -CH2-, -CHME-) UNIDO A LA POSICION * EN EL ANILLO FENILO PARA FORMAR UN HETEROCICLO DE 6 MIEMBROS FUSIONADOS QUE CONTIENE N; R5 ES BENCILO SUSTITUIDO O NO POR 1 O MAS GRUPOS F, CL, CN, METILO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES ESTER ISOPROPILICO DEL ACIDO (S)-4-(5-{4-[2-AMINO-3-((S)-2-CIANOPIRROLIDIN-1-IL)-3-OXOPROPIL]-3-FLUOROFENIL}-PIRIDIN-2-ILOXIMETIL)-PIPERIDIN-1-CARBOXILICO. DICHOS COMPUESTOS SON AGONISTAS DE GPR119, UTILES EN EL TRATAMIENTO DE TRASTORNOS METABOLICOS QUE INCLUYEN LA DIABETES TIPO II
PE2011001632A 2009-03-12 2010-03-12 Compuesto para el tratamiento de trastornos metabolicos PE20120657A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0904284.7A GB0904284D0 (en) 2009-03-12 2009-03-12 Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
PE20120657A1 true PE20120657A1 (es) 2012-06-27

Family

ID=40600945

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001632A PE20120657A1 (es) 2009-03-12 2010-03-12 Compuesto para el tratamiento de trastornos metabolicos

Country Status (18)

Country Link
US (1) US20120077793A1 (es)
EP (1) EP2406247A1 (es)
JP (1) JP2012520282A (es)
KR (1) KR20110133044A (es)
CN (1) CN102348703A (es)
AU (1) AU2010222671A1 (es)
BR (1) BRPI1013245A2 (es)
CA (1) CA2754709A1 (es)
CL (1) CL2011002181A1 (es)
EA (1) EA201190208A1 (es)
GB (1) GB0904284D0 (es)
IL (1) IL215049A0 (es)
MA (1) MA33190B1 (es)
MX (1) MX2011009490A (es)
PE (1) PE20120657A1 (es)
SG (1) SG174279A1 (es)
WO (1) WO2010103333A1 (es)
ZA (1) ZA201107445B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803214A (zh) 2009-06-24 2012-11-28 贝林格尔.英格海姆国际有限公司 新化合物、与之相关的药物组合物和方法
EP2445901A1 (en) 2009-06-24 2012-05-02 Boehringer Ingelheim International GmbH New compounds, pharmaceutical composition and methods relating thereto
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012066077A1 (en) 2010-11-18 2012-05-24 Prosidion Limited 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
US8853239B2 (en) * 2011-12-09 2014-10-07 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
KR101719321B1 (ko) * 2016-03-31 2017-03-23 충남대학교산학협력단 3-(4-클로로페닐)벤조[4, 5]이미다조[2, 1-b]싸이아졸-6-카복실산을 포함하는 항비만 또는 항우울증 치료용 조성물
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法
WO2023208081A1 (en) * 2022-04-28 2023-11-02 Shenzhen Bay Laboratory Substituted fluorosulfate and use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
JP2002523090A (ja) 1998-09-01 2002-07-30 ビーエーエスエフ アクチェンゲゼルシャフト 異種ｇタンパク質共役受容体の増強された機能的発現
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
EP1562925B1 (en) * 2002-11-07 2007-01-03 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP4958560B2 (ja) 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
JP4980928B2 (ja) 2004-12-24 2012-07-18 プロシディオン・リミテッド Ｇタンパク質共役受容体（ｇｐｒ１１６）作動薬および肥満および糖尿病治療のためのその使用
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
CA2613236A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
KR20080109075A (ko) 2006-04-06 2008-12-16 프로시디온 리미티드 헤테로사이클릭 ｇｐｃｒ 작용제
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
MY157365A (en) * 2006-12-06 2016-05-31 Smithkline Beecham Corp Chemical compounds and uses
ATE523507T1 (de) 2007-01-04 2011-09-15 Prosidion Ltd Piperidin-gpcr-agonisten
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
CN101827958A (zh) 2007-10-18 2010-09-08 日矿金属株式会社 金属包覆的聚酰亚胺复合体、该复合体的制造方法以及电子电路板的制造方法
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
CN101621337B (zh) 2008-06-30 2013-08-07 华为技术有限公司 一种时延调节装置与方法
ES2387865T3 (es) 2008-07-10 2012-10-03 Prosidion Ltd Agonistas de GPCR de piperidina
MX2011000060A (es) 2008-07-10 2011-02-22 Prosidion Ltd Agonistas del receptor acoplado a la proteina g piperidinilo.
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds

Also Published As

Publication number Publication date
US20120077793A1 (en) 2012-03-29
CA2754709A1 (en) 2010-09-16
EP2406247A1 (en) 2012-01-18
WO2010103333A1 (en) 2010-09-16
EA201190208A1 (ru) 2012-04-30
CN102348703A (zh) 2012-02-08
MA33190B1 (fr) 2012-04-02
CL2011002181A1 (es) 2012-05-04
ZA201107445B (en) 2012-06-27
JP2012520282A (ja) 2012-09-06
AU2010222671A1 (en) 2011-11-03
BRPI1013245A2 (pt) 2016-04-05
SG174279A1 (en) 2011-10-28
GB0904284D0 (en) 2009-04-22
KR20110133044A (ko) 2011-12-09
MX2011009490A (es) 2011-10-11
IL215049A0 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP088479A (es) Derivados de oxadiazol
AR083635A1 (es) Compuestos y derivados sustituidos de isoxazolina que contienen azolin para combatir plagas animales
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
AR059516A1 (es) Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas
AR087196A1 (es) Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii
PE20150339A1 (es) Carboxamidas heterociclicas fungicidas
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
AR073136A1 (es) Compuestos de pirrol
AR077818A1 (es) Composiciones pesticidas
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
AR075635A1 (es) N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos
PE20091096A1 (es) Compuestos organicos
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20110906A1 (es) Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
PE20142282A1 (es) Nuevos derivados de aril-quinolina
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20090592A1 (es) Nuevos derivados de piperazina-amida

Legal Events

Date Code Title Description
FD Application declared void or lapsed